The pre-B-cell receptor checkpoint in acute lymphoblastic leukaemia.

Abstract:

:The B-cell receptor (BCR) and its immature form, the precursor-BCR (pre-BCR), have a central role in the control of B-cell development, which is dependent on a sequence of cell-fate decisions at specific antigen-independent checkpoints. Pre-BCR expression provides the first checkpoint, which controls differentiation of pre-B to immature B-cells in normal haemopoiesis. Pre-BCR signalling regulates and co-ordinates diverse processes within the pre-B cell, including clonal selection, proliferation and subsequent maturation. In B-cell precursor acute lymphoblastic leukaemia (BCP-ALL), B-cell development is arrested at this checkpoint. Moreover, malignant blasts avoid clonal extinction by hijacking pre-BCR signalling in favour of the development of BCP-ALL. Here, we discuss three mechanisms that occur in different subtypes of BCP-ALL: (i) blocking pre-BCR expression; (ii) activating pre-BCR-mediated pro-survival and pro-proliferative signalling, while inhibiting cell cycle arrest and maturation; and (iii) bypassing the pre-BCR checkpoint and activating pro-survival signalling through pre-BCR independent alternative mechanisms. A complete understanding of the BCP-ALL-specific signalling networks will highlight their application in BCP-ALL therapy.

journal_name

Leukemia

journal_title

Leukemia

authors

Eswaran J,Sinclair P,Heidenreich O,Irving J,Russell LJ,Hall A,Calado DP,Harrison CJ,Vormoor J

doi

10.1038/leu.2015.113

subject

Has Abstract

pub_date

2015-08-01 00:00:00

pages

1623-31

issue

8

eissn

0887-6924

issn

1476-5551

pii

leu2015113

journal_volume

29

pub_type

杂志文章,评审

相关文献

LEUKEMIA文献大全
  • Synergistic effect of AS101 and Bryostatin-1 on myeloid leukemia cell differentiation in vitro and in an animal model.

    abstract::We evaluated the synergistic activity of AS101 (ammonium trichloro-(dioxoethylene-0-0')-tellurate) with the protein kinase C (PKC) activators, Bryostatin-1 and phorbol-12-myristate-13-acetate (PMA), on human myelocytic leukemia cell differentiation in vitro, and in a mouse model. Use of AS101 with Bryostatin-1 or with...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404746

    authors: Hayun M,Okun E,Hayun R,Gafter U,Albeck M,Longo DL,Sredni B

    更新日期:2007-07-01 00:00:00

  • Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia: results in patients treated in second molecular remission or with molecularly persistent disease.

    abstract::In all, 17 consecutive patients in hematological complete remission (HCR) of acute promyelocytic leukemia (APL) received allogeneic stem cell transplantation (SCT) from an HLA-identical sibling and were monitored by reverse transcriptase polymerase chain reaction of PML/RARalpha prior and after transplant. Median age ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403078

    authors: Lo-Coco F,Romano A,Mengarelli A,Diverio D,Iori AP,Moleti ML,De Santis S,Cerretti R,Mandelli F,Arcese W

    更新日期:2003-10-01 00:00:00

  • Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.

    abstract::Renal impairment is associated with poor prognosis in multiple myeloma (MM). This subgroup analysis of the phase 3 Assessment of Proteasome Inhibition for Extending Remissions (APEX) study of bortezomib vs high-dose dexamethasone assessed efficacy and safety in patients with relapsed MM with varying degrees of renal i...

    journal_title:Leukemia

    pub_type: 杂志文章,随机对照试验

    doi:10.1038/sj.leu.2405087

    authors: San-Miguel JF,Richardson PG,Sonneveld P,Schuster MW,Irwin D,Stadtmauer EA,Facon T,Harousseau JL,Ben-Yehuda D,Lonial S,Goldschmidt H,Reece D,Bladé J,Boccadoro M,Cavenagh JD,Neuwirth R,Boral AL,Esseltine DL,Anderson KC

    更新日期:2008-04-01 00:00:00

  • Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia.

    abstract::The fms-related tyrosine kinase 3 (FLT3) receptor has been extensively studied over the past two decades with regard to oncogenic alterations that do not only serve as prognostic markers but also as therapeutic targets in acute myeloid leukemia (AML). Internal tandem duplications (ITDs) became of special interest in t...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2017.257

    authors: Reiter K,Polzer H,Krupka C,Maiser A,Vick B,Rothenberg-Thurley M,Metzeler KH,Dörfel D,Salih HR,Jung G,Nößner E,Jeremias I,Hiddemann W,Leonhardt H,Spiekermann K,Subklewe M,Greif PA

    更新日期:2018-02-01 00:00:00

  • IL-6 trans-signaling promotes the expansion and anti-tumor activity of CAR T cells.

    abstract::Chimeric antigen receptor (CAR) T cell therapies lead to high clinical response rates in B cell malignancies, and are under investigation for treatment of solid tumors. While high systemic interleukin- (IL-) 6 levels are associated with clinical cytokine release syndrome (CRS), the role of IL-6 trans-signaling within ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-020-01085-1

    authors: Jiang Z,Liao R,Lv J,Li S,Zheng D,Qin L,Wu D,Chen S,Long Y,Wu Q,Wang S,Lin S,Huang X,Tang Z,Shi P,Zhou H,Liu Q,Zhao R,Li Y,Jie Y,Wei W,Lai P,Du X,Cui S,Weinkove R,Liu P,Pei D,Yao Y,Li P

    更新日期:2020-11-09 00:00:00

  • A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis.

    abstract::Myelofibrosis (MF; primary or post-essential thrombocythemia/polycythemia vera) is incurable clonal myeloproliferative disorder, with no effective treatment. Epigenetic changes play an important role in cancer pathogenesis through transcriptional silencing of critical tumor suppressor genes. We conducted a phase-II st...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2008.91

    authors: Quintás-Cardama A,Tong W,Kantarjian H,Thomas D,Ravandi F,Kornblau S,Manshouri T,Cortes JE,Garcia-Manero G,Verstovsek S

    更新日期:2008-05-01 00:00:00

  • FHL2 regulates hematopoietic stem cell functions under stress conditions.

    abstract::FHL2, a member of the four and one half LIM domain protein family, is a critical transcriptional modulator. Here, we identify FHL2 as a critical regulator of hematopoietic stem cells (HSCs) that is essential for maintaining HSC self-renewal under regenerative stress. We find that Fhl2 loss has limited effects on hemat...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2014.254

    authors: Hou Y,Wang X,Li L,Fan R,Chen J,Zhu T,Li W,Jiang Y,Mittal N,Wu W,Peace D,Qian Z

    更新日期:2015-03-01 00:00:00

  • Secondary chromosomal abnormalities in acute leukemias.

    abstract::Secondary chromosomal aberrations reported in the literature were surveyed in acute myeloid or lymphoblastic leukemia (AML or ALL) with one of the following primary abnormalities: in AML, t(1;3), t(1;22), der(1;7), inv(3), t(3;5) +4, del(5q), t(6;9), -7, t(7;11), del(7q), +8, t(8;16), t(8;21), +9, t(9;11), del(9q), t(...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Johansson B,Mertens F,Mitelman F

    更新日期:1994-06-01 00:00:00

  • Specific point mutations that activate v-abl are not found in Philadelphia-negative chronic myeloid leukaemia, Philadelphia-negative acute lymphoblastic leukaemia or blast transformation of chronic myeloid leukaemia.

    abstract::The involvement of the BCRlABL fusion gene in patients with Philadelphia (Ph) chromosome positive chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL) is well characterised, but the molecular events underlying the cases of Ph-negative CML and ALL that lack BCR gene involvement and those that cause t...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Melo JV,Goldman JM

    更新日期:1992-08-01 00:00:00

  • Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients.

    abstract::Unlike the case with acute myeloid leukemia, there is limited information on the prognostic impact of isocitrate dehydrogenase (IDH) mutations in myelodysplastic syndromes (MDS). In the current study of 277 patients with MDS, IDH mutations were detected in 34 (12%) cases: 26 IDH2 (all R140Q) and 8 IDH1 (6 R132S and 2 ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2011.298

    authors: Patnaik MM,Hanson CA,Hodnefield JM,Lasho TL,Finke CM,Knudson RA,Ketterling RP,Pardanani A,Tefferi A

    更新日期:2012-01-01 00:00:00

  • ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells.

    abstract::Disruption of pathways leading to programmed cell death plays a major role in most malignancies, including multiple myeloma (MM). ABT-737 is a BH3 mimetic small-molecule inhibitor that binds with high affinity to Bcl-2 and Bcl-xL, preventing the sequestration of proapoptotic molecules and shifting the cell survival/ap...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404719

    authors: Kline MP,Rajkumar SV,Timm MM,Kimlinger TK,Haug JL,Lust JA,Greipp PR,Kumar S

    更新日期:2007-07-01 00:00:00

  • Disruption of the BCL11B gene through inv(14)(q11.2q32.31) results in the expression of BCL11B-TRDC fusion transcripts and is associated with the absence of wild-type BCL11B transcripts in T-ALL.

    abstract::T-cell acute lymphoblastic leukemia (T-ALL) is associated with chromosomal aberrations characterized by juxtaposition of proto-oncogenes to T-cell receptor gene loci (TCR), resulting in the deregulated transcription of these proto-oncogenes. Here, we describe the molecular characterization of a novel chromosomal aberr...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403619

    authors: Przybylski GK,Dik WA,Wanzeck J,Grabarczyk P,Majunke S,Martin-Subero JI,Siebert R,Dölken G,Ludwig WD,Verhaaf B,van Dongen JJ,Schmidt CA,Langerak AW

    更新日期:2005-02-01 00:00:00

  • Leukemic dendritic cells generated in the presence of FLT3 ligand have the capacity to stimulate an autologous leukemia-specific cytotoxic T cell response from patients with acute myeloid leukemia.

    abstract::It has been proposed that adoptive immunotherapy, for the treatment of relapsed AML, with cytotoxic T lymphocytes which show a relative specificity for the leukemic cells may have the advantage of maximizing the beneficial anti-leukemic effect whilst minimizing the probability of graft-versus-host disease. In this stu...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402013

    authors: Woiciechowsky A,Regn S,Kolb HJ,Roskrow M

    更新日期:2001-02-01 00:00:00

  • Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies.

    abstract::The nuclear export receptor, Exportin 1 (XPO1), mediates transport of growth-regulatory proteins, including tumor suppressors, and is overactive in many cancers, including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML) and aggressive lymphomas. Oral selective inhibitor of nuclear export (SINE) compou...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2016.136

    authors: Hing ZA,Fung HY,Ranganathan P,Mitchell S,El-Gamal D,Woyach JA,Williams K,Goettl VM,Smith J,Yu X,Meng X,Sun Q,Cagatay T,Lehman AM,Lucas DM,Baloglu E,Shacham S,Kauffman MG,Byrd JC,Chook YM,Garzon R,Lapalombella R

    更新日期:2016-12-01 00:00:00

  • Neutralization of (NK-cell-derived) B-cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis.

    abstract::Natural killer (NK) cells are cytotoxic lymphocytes that substantially contribute to the therapeutic benefit of antitumor antibodies like Rituximab, a crucial component in the treatment of B-cell malignancies. In chronic lymphocytic leukemia (CLL), the ability of NK cells to lyse the malignant cells and to mediate ant...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2015.50

    authors: Wild J,Schmiedel BJ,Maurer A,Raab S,Prokop L,Stevanović S,Dörfel D,Schneider P,Salih HR

    更新日期:2015-08-01 00:00:00

  • Cloning and sequence analysis of four t(9;11) therapy-related leukemia breakpoints.

    abstract::The t(9;11)(p22;q23) is the most common chromosomal translocation in topoisomerase II inhibitor therapy-related acute myeloid leukemia (tAML). This translocation fuses the MLL and AF9 proto-oncogenes producing a novel chimeric protein. In order to gain insight into the mechanism generating the t(9;11) and to clarify t...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401223

    authors: Atlas M,Head D,Behm F,Schmidt E,Zeleznik-Le NH,Roe BA,Burian D,Domer PH

    更新日期:1998-12-01 00:00:00

  • Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection.

    abstract::Chimeric antigen receptor (CAR)-T-cell is a safe and effective therapy of B-cell cancers but it is unknown if this is so in persons with prior hepatitis B virus (HBV) infection. We studied 70 subjects with advanced B-cell cancers receiving CAR-T-cell therapy, 12 of whom had chronic HBV-infection (HBsAg positive) and 2...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-020-0936-4

    authors: Wang Y,Liu Y,Tan X,Pan B,Ge J,Qi K,Cheng H,Cao J,Shi M,Yan Z,Qiao J,Jing G,Wang X,Sang W,Xia R,Zhang X,Li Z,Gale RP,Zheng J,Zhu F,Xu K

    更新日期:2020-10-01 00:00:00

  • DPP4 truncated GM-CSF and IL-3 manifest distinct receptor-binding and regulatory functions compared with their full-length forms.

    abstract::Dipeptidylpeptidase 4 (DPP4/CD26) enzymatically cleaves select penultimate amino acids of proteins, including colony-stimulating factors (CSFs), and has been implicated in cellular regulation. To better understand the role of DPP4 regulation of hematopoiesis, we analyzed the activity of DPP4 on the surface of immature...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2017.98

    authors: O'Leary HA,Capitano M,Cooper S,Mantel C,Boswell HS,Kapur R,Ramdas B,Chan R,Deng L,Qu CK,Broxmeyer HE

    更新日期:2017-11-01 00:00:00

  • Collection, analysis and transplantation of Ph-negative blood precursor cells in chronic myeloid leukemia.

    abstract::This work represents an update of our experience on mobilization and transplantation of peripheral blood progenitor cells (PBPC) collected during the early recovery phase after chemotherapy in patients with chronic myelogenous leukemia. The collection of Ph-negative precursor cells occurred in 13/19 (68%) patients mob...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Frassoni F,Carella AM

    更新日期:1996-06-01 00:00:00

  • Resistance circumvention strategies tested in clinical leukaemia specimens using the MTT colorimetric assay.

    abstract::We have used a 4-day MTT colorimetric assay to study drug sensitivity of leucocytes from leukaemia patients and from normal donors. Response to Adriamycin, vincristine, aclacinomycin A, 3'-deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin (MX2), and melphalan has been determined, together with the effects of the r...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Lambert E,Rees JK,Twentyman PR

    更新日期:1992-10-01 00:00:00

  • Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study.

    abstract::Data on outcome in older (≥70 years) patients with acute promyelocytic leukemia after treatment with arsenic trioxide (ATO) compared with standard chemotherapy (CTX) is scarce. We evaluated 433 patients (median age, 73.4 years) treated either with ATO+ all-trans retinoic acid (ATO/ATRA; n = 26), CTX/ATRA + ATO during ...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/s41375-020-0758-4

    authors: Kayser S,Rahmé R,Martínez-Cuadrón D,Ghiaur G,Thomas X,Sobas M,Guerci-Bresler A,Garrido A,Pigneux A,Gil C,Raffoux E,Tormo M,Vey N,de la Serna J,Salamero O,Lengfelder E,Levis MJ,Fenaux P,Sanz MA,Platzbecker U,Schlen

    更新日期:2020-09-01 00:00:00

  • Somatic mitochondrial DNA mutations in adult-onset leukaemia.

    abstract::Mitochondrial genome instability has recently been demonstrated in a wide variety of human tumours and is implicated in the development of the myelodysplastic syndromes, a heterogeneous group of haematological disorders with an increased risk of malignant transformation. We therefore investigated the incidence of soma...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403146

    authors: He L,Luo L,Proctor SJ,Middleton PG,Blakely EL,Taylor RW,Turnbull DM

    更新日期:2003-12-01 00:00:00

  • Expression of the monocyte-specific esterase gene in leukemia-lymphoma cell lines.

    abstract::The expression of the monocyte esterase was examined in a panel of 77 continuous human leukemia-lymphoma cell lines representing all hematopoietic cell lineages and in 16 other cell lines. Accumulation of mRNA, determined by Northern blotting with the cDNA probe HMSE-1, and production of the protein, shown by isoelect...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Uphoff CC,Gignac SM,Metge K,Zschunke F,Radzun HJ,Drexler HG

    更新日期:1993-01-01 00:00:00

  • Translocation t(1;22) mimicking t(1;19) in a child with acute lymphoblastic leukemia as revealed by chromosome painting.

    abstract::The karyotype of a boy with acute lymphoblastic leukemia (ALL) presenting with numerical and structural chromosome aberrations as determined by Giemsa-banding was further investigated using chromosome painting (CP). A translocation t(11;18)(q23;q21) was verified by this approach, and gain of chromosome 21 material due...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Rieder H,Kolbus U,Koop U,Ludwig WD,Stollmann-Gibbels B,Fonatsch C

    更新日期:1993-10-01 00:00:00

  • Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma.

    abstract::Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-a subtype of Hodgkin lymphoma (HL)-is characterized by a low content of tumor cells, the lymphocyte predominant (LP) cells. Transformation into diffuse large B-cell lymphoma (DLBCL) occurs in about 10% of patients. We performed whole-genome mutation analysis of t...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2015.328

    authors: Hartmann S,Schuhmacher B,Rausch T,Fuller L,Döring C,Weniger M,Lollies A,Weiser C,Thurner L,Rengstl B,Brunnberg U,Vornanen M,Pfreundschuh M,Benes V,Küppers R,Newrzela S,Hansmann ML

    更新日期:2016-04-01 00:00:00

  • Recognition of the ALL-specific BCR-ABL junction in P190bcr-abl by monoclonal antibody ER-FP1.

    abstract::The pH chromosome, resulting from the t(9;22) translocation, is the most frequently observed cytogenetic aberration in acute lymphoblastic leukemia (ALL). Two genes, bcr and abl, are involved in this translocation. As a consequence, parts of the bcr and abl genes are fused, resulting in chimeric bcr-abl genes encoding...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: van Denderen J,ten Hacken P,Berendes P,Zegers N,Boersma W,Grosveld G,van Ewijk W

    更新日期:1994-09-01 00:00:00

  • Ibrutinib reprograms the glucocorticoid receptor in chronic lymphocytic leukemia cells.

    abstract::Glucocorticoid (GC) receptor (GR) phosphorylation and signature genes were studied in chronic lymphocytic leukemia (CLL) cells to help place GCs within modern treatment algorithms. In contrast to normal B and T cells, transcription of GC-regulated genes was not rhythmic and the synthetic GC dexamethasone (DEX) could n...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-019-0381-4

    authors: Shi Y,Wang G,Muhowski EM,McCaw L,Wang C,Bjarnason G,Woyach JA,Spaner DE

    更新日期:2019-07-01 00:00:00

  • Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System.

    abstract::Allogeneic hematopoietic stem cell transplantation (allo-SCT) represents the only curative treatment for patients with myelodysplastic syndrome (MDS), but involves non-negligible morbidity and mortality. Crucial questions in clinical decision-making include the definition of optimal timing of the procedure and the ben...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2017.88

    authors: Della Porta MG,Jackson CH,Alessandrino EP,Rossi M,Bacigalupo A,van Lint MT,Bernardi M,Allione B,Bosi A,Guidi S,Santini V,Malcovati L,Ubezio M,Milanesi C,Todisco E,Voso MT,Musto P,Onida F,Iori AP,Cerretti R,Grillo

    更新日期:2017-11-01 00:00:00

  • Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer.

    abstract::Hemizygous deletions are common molecular abnormalities in cancer. In some cases, these deletions highlight chromosomal loci containing tumor suppressor genes that undergo homozygous inactivation. In other cases, hemizygous deletions cause disease by allelic insufficiency for one or more genes. As the intact allele ha...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/leu.2009.53

    authors: Ebert BL

    更新日期:2009-07-01 00:00:00

  • Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.

    abstract::Previous studies in pediatric patients with acute myelogenous leukemia (AML) have suggested that 2-chlorodeoxyadenosine (2CdA) is an effective therapeutic agent. Santana et al (J Clin Oncol 1992; 10: 364-370) reported a CR rate of 8/17 (95% Cl 23-72%) in children with relapsed AML and a median first CR of 21 months. T...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章

    doi:

    authors: Kornblau SM,Gandhi V,Andreeff HM,Beran M,Kantarjian HM,Koller CA,O'Brien S,Plunkett W,Estey E

    更新日期:1996-10-01 00:00:00